Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
In the trial, an increase in total Hammersmith Functional Motor Scale – Expanded scores was reported.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
